Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22732754 | 0.86 | KMT2A (0.43) | KMT2AMAPTTP53ACACBPARP10 | |
| SCHEMBL22732834 | 0.80 | MAPT (0.47) | RXRANR4A2KMT2AMAPTTP53 | |
| SCHEMBL22732764 | 0.79 | KDM4E (0.40) | KMT2AMAPTTP53ACACBPARP10 | |
| SCHEMBL22712504 | 0.78 | KMT2A (0.56) | RXRANR4A2KMT2AMAPTTP53 | |
| SCHEMBL8270868 | 0.76 | PARP10 (0.38) | KMT2AMAPTTP53ACACBPARP10 | |
| SCHEMBL10073169 | 0.76 | RXRA (0.56) | RXRANR4A2KMT2ATP53 | |
| SCHEMBL22712537 | 0.75 | KMT2A (0.45) | KMT2AMAPTTP53ACACBPARP10 | |
| SCHEMBL22732811 | 0.74 | RAB9A (0.53) | RXRANR4A2MAPTTP53XDH | |
| SCHEMBL1321790 | 0.73 | NPSR1 (0.37) | KMT2AMAPTTP53ACACBMCL1 | |
| SCHEMBL26228637 | 0.73 | KMT2A (0.44) | KMT2AMAPTTP53ACACBPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289480-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-20220135528-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. (US AND US TERRITORIES) | 2022-05-05 | — | — | US | disclosed |
| US-11208387-B2 | Macrocyclic broad spectrum antibiotics | GENENTECH, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200377463-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377463-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, CLPP, PEPD | RXRA 2669/4885NR4A2 3206/4885KMT2A 3444/4885 |
| US-20220135528-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, CLPP, PEPD | RXRA 2669/4885NR4A2 3206/4885KMT2A 3444/4885 |
| US-11208387-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, CLPP, PEPD | RXRA 2669/4885NR4A2 3206/4885KMT2A 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.